Swiss National Bank Has $1.09 Million Stock Holdings in Bicara Therapeutics Inc. $BCAX

Swiss National Bank increased its stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) by 70.3% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 55,000 shares of the company’s stock after acquiring an additional 22,700 shares during the quarter. Swiss National Bank’s holdings in Bicara Therapeutics were worth $1,094,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Vestal Point Capital LP raised its holdings in Bicara Therapeutics by 2.0% in the 3rd quarter. Vestal Point Capital LP now owns 5,100,000 shares of the company’s stock valued at $80,529,000 after acquiring an additional 100,000 shares during the period. T. Rowe Price Investment Management Inc. lifted its position in Bicara Therapeutics by 596.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock worth $54,472,000 after acquiring an additional 2,771,868 shares during the last quarter. Janus Henderson Group PLC bought a new stake in shares of Bicara Therapeutics during the fourth quarter worth approximately $44,484,000. Vanguard Group Inc. boosted its holdings in shares of Bicara Therapeutics by 9.8% during the third quarter. Vanguard Group Inc. now owns 2,200,925 shares of the company’s stock worth $34,753,000 after acquiring an additional 195,667 shares during the period. Finally, State Street Corp grew its position in shares of Bicara Therapeutics by 179.5% in the fourth quarter. State Street Corp now owns 1,649,537 shares of the company’s stock valued at $27,762,000 after purchasing an additional 1,059,260 shares during the last quarter.

Analyst Ratings Changes

BCAX has been the topic of a number of recent research reports. The Goldman Sachs Group increased their target price on Bicara Therapeutics from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 12th. Cantor Fitzgerald restated an “overweight” rating on shares of Bicara Therapeutics in a research note on Wednesday, May 27th. Morgan Stanley upped their price objective on Bicara Therapeutics from $36.00 to $37.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. Guggenheim began coverage on Bicara Therapeutics in a research report on Monday, May 11th. They set a “buy” rating and a $42.00 price objective on the stock. Finally, Wall Street Zen upgraded Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, May 24th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Bicara Therapeutics has an average rating of “Moderate Buy” and an average price target of $30.27.

Insider Activity at Bicara Therapeutics

In other Bicara Therapeutics news, COO Ryan Cohlhepp sold 28,214 shares of the firm’s stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $28.98, for a total transaction of $817,641.72. Following the transaction, the chief operating officer owned 182,177 shares in the company, valued at $5,279,489.46. This trade represents a 13.41% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ivan Hyep sold 28,000 shares of Bicara Therapeutics stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $28.85, for a total value of $807,800.00. Following the completion of the transaction, the chief financial officer directly owned 129,855 shares of the company’s stock, valued at $3,746,316.75. This represents a 17.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 88,450 shares of company stock worth $2,366,675. Company insiders own 13.80% of the company’s stock.

Bicara Therapeutics Stock Up 3.2%

NASDAQ BCAX opened at $27.10 on Friday. The firm has a 50-day moving average price of $25.19 and a two-hundred day moving average price of $21.20. Bicara Therapeutics Inc. has a 12-month low of $9.57 and a 12-month high of $30.99. The company has a market capitalization of $1.78 billion, a P/E ratio of -9.75 and a beta of -0.81.

Bicara Therapeutics (NASDAQ:BCAX) last announced its earnings results on Monday, May 11th. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.21). Equities analysts expect that Bicara Therapeutics Inc. will post -3.42 EPS for the current year.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.